Doxorubicin hydrochloride (CAS 25316-40-9) is a classic anthracycline antitumor antibiotic widely used in chemotherapy for a variety of solid and hematologic malignancies, including breast cancer, lymphomas and leukemias. It is isolated from Streptomyces peucetius and is known for its characteristic red colour and high cytotoxicity.
On the TCS INDUSTRIES LIMITED website,
is presented as an oncology API for injectable formulations. Mechanistically, doxorubicin intercalates into DNA, inhibiting nucleic acid synthesis, and inhibits topoisomerase II, leading to double-strand breaks and apoptosis in rapidly dividing cells.
As a high-potency cytotoxic agent with a narrow therapeutic window and known risks such as cumulative cardiotoxicity, doxorubicin HCl requires specialised manufacturing, containment and handling. TCS GROUP supports partners with detailed impurity profiles, stability guidance and regulatory documentation to meet stringent oncology standards.
Doxorubicin HCl is a cornerstone of the TCS
Active Pharmaceutical Ingredient
portfolio in oncology, where it is complemented by other chemotherapeutics such as:
- Carmustine 154-93-8 – an alkylating nitrosourea used in brain tumours and other malignancies.
- Chlorambucil 305-03-3 – an oral nitrogen mustard for CLL and certain lymphomas.
- Daptomycin 103060-53-3 – while an antibiotic, it often appears in the same hospital setting as oncology drugs, underscoring TCS’s experience in critical-care injectables.
Formulating doxorubicin HCl typically involves lyophilised or solution-based injectables with strict control over pH, ionic strength and diluent compatibility. Packaging systems must guard against light and ensure correct reconstitution and administration in clinical settings. Process validation, operator protection and waste management are all crucial aspects of working with this API.
By choosing Doxorubicin HCl 25316-40-9 from TCS INDUSTRIES LIMITED, oncology manufacturers gain access to a well-characterised anthracycline API backed by robust quality systems, extensive documentation and a complementary range of chemotherapeutic and hospital anti-infective APIs, enabling comprehensive treatment regimens in modern cancer care.